Skip to main content
Journal ArticleOPEN ACCESS

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

  • Shimokihara K
  • Kawahara T
  • Suzuki T
  • et al.
Clinical Case Reports (2018) 6(2) 391-394
DOI: 10.1002/ccr3.1328
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Cite

CITATION STYLE

APA

Shimokihara, K., Kawahara, T., Suzuki, T., Mochizuki, T., Takamoto, D., Teranishi, J., … Uemura, H. (2018). Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report. Clinical Case Reports, 6(2), 391–394. https://doi.org/10.1002/ccr3.1328

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free